Simple, inexpensive drugs to treat COVID are few and far between. But we may have a new, old pill to add to the arsenal. A new study tells us how well it works.
The Lancet reports on a polypill containing aspirin, blood pressure medicine and a statin. For a large at-risk population, it reduced major cardiovascular events by 20 to 33% ... and for about $1.25 a month.
The pain relief counter in your pharmacy can be a confusing place ... enough so to give you a headache. But actually, it can all be very simple. There are four over-the-counter painkillers, some of which can be taken together and some of which can't. Here's the scoop, presented in a way that's easy to swallow. 
Baby aspirin just flunked the test of preventing cardiovascular problems, in a big way. The results of ARRIVE, or "Aspirin to Reduce Risk of Initial Vascular Events," were just announced at the European Society of Cardiology 2018 meeting in Munich. Does this mean that recommendations for its use will change? Probably yes.  
Baby aspirin is prescribed for many people who, as it turns out, will experience no benefit. It results from the difficulty in reconciling population studies with the patient in front of you. Doctors end up broadening the groups. Call it "Indication Creep."  
A debate is on over the benefits of taking aspirin for those without a history of prior cardiovascular disease. The current thinking advocates using low-dose aspirin, for primary prevention, in certain high risk groups: those with advanced age, diabetes, high cholesterol, high blood pressure and smoking. But not so, says a new study from Japan. 
The United States Preventive Services Task Force has issued its final recommendations for aspirin use, as it applies to the prevention of cardiovascular disease and colorectal cancer. It mostly pertains to those in the 50-to-59 and 60-to-69 age groups.
The world s largest clinical trial on aspirin was recently held in the United Kingdom, looking to determine whether taking daily aspirin will stop cancer, or delay its recurrence. Evidence suggests a reduction in colorectal polyps and cancer with aspirin use, depending on the dose and duration of therapy.
For the first time, the official federal health panel has recommended aspirin to protect against colorectal cancer, as well as heart attack and stroke. But the guidance is far from clear-cut, with age restrictions and numerous caveats.
A new study links long-term, continuous use of common painrelievers (NSAIDs and aspirin) to a reduced risk of colorectal cancer (CRC). This study does not prove a cause-and-effect benefit, and these drugs can cause bleeding, so discuss with your doctor.
It is generally accepted that the chronic use of aspirin and some other non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colorectal cancer (CRC). A new study shows that this beneficial effect may not apply to everyone.
The use of low doses of aspirin is known to decrease the risk of both colorectal cancer (CRC) and cardiovascular disease (CVD). On the other hand, chronic aspirin use can also cause gastrointestinal (GI) bleeding which can be severe. So how should one make the decision as to whether or not to use aspirin?